Suppr超能文献

嵌合抗原受体T细胞疗法在神经病学中的当前及未来作用:综述

Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review.

作者信息

Ismail Fatme Seval, Gallus Marco, Meuth Sven G, Okada Hideho, Hartung Hans-Peter, Melzer Nico

机构信息

Department of Neurology, Klinikum Vest, Academic Teaching Hospital of the Ruhr University Bochum, Recklinghausen, Germany.

Department of Neurological Surgery, University of California, San Francisco.

出版信息

JAMA Neurol. 2025 Jan 1;82(1):93-103. doi: 10.1001/jamaneurol.2024.3818.

Abstract

IMPORTANCE

Advancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field of neurology, particularly for primary brain tumors and autoimmune neurological disorders.

OBSERVATIONS

CAR T-cell therapy for glioblastoma is promising; however, first-in-human trials did not yield significant success or showed only limited success in a subset of patients. To date, the efficacy of CAR T-cell therapies has been demonstrated in animal models of multiple sclerosis, but larger human studies to corroborate the efficacy remain pending. CAR T cells showed efficacy in treatment of patients with relapsed or refractory aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorders. Further studies with larger patient populations are needed to confirm these results. Success was reported also for treatment of cases with generalized myasthenia gravis using CAR T cells. Chimeric autoantibody receptor T cells, representing a modified form of CAR T cells directed against autoreactive B cells secreting autoantibodies, were used to selectively target autoreactive anti-N-methyl-d-aspartate B cells under in vitro and in vivo conditions, providing the basis for human studies and application to other types of autoimmune encephalitis associated with neuronal or glial antibodies.

CONCLUSIONS AND RELEVANCE

CAR T cells herald a new era in the therapeutic landscape of neurological disorders. While their application in solid tumors, such as glioblastoma, has not universally yielded robust success, emerging innovative strategies show promise, and there is optimism for their effectiveness in certain autoimmune neurological disorders.

摘要

重要性

分子工程学的进展推动了表达合成受体(称为嵌合抗原受体,CAR)的工程化T细胞的创建。这不仅在癌症治疗中前景广阔,而且在解决一系列其他病症方面也颇具潜力。本综述全面概述了CAR T细胞疗法在神经病学领域,特别是原发性脑肿瘤和自身免疫性神经疾病方面的当前方法和未来潜力。

观察结果

CAR T细胞疗法治疗胶质母细胞瘤颇具前景;然而,首次人体试验并未取得显著成功,或仅在部分患者中显示出有限的成功。迄今为止,CAR T细胞疗法的疗效已在多发性硬化症动物模型中得到证实,但仍有待更大规模的人体研究来证实其疗效。CAR T细胞在治疗复发或难治性水通道蛋白4免疫球蛋白G血清阳性视神经脊髓炎谱系障碍患者中显示出疗效。需要更多患者参与的进一步研究来证实这些结果。也有报道称使用CAR T细胞治疗全身性重症肌无力病例取得了成功。嵌合自身抗体受体T细胞是针对分泌自身抗体的自身反应性B细胞的一种改良形式的CAR T细胞,用于在体外和体内条件下选择性靶向自身反应性抗N-甲基-D-天冬氨酸B细胞,为人体研究以及应用于与神经元或神经胶质抗体相关的其他类型自身免疫性脑炎提供了基础。

结论与意义

CAR T细胞开创了神经疾病治疗领域的新纪元。虽然它们在实体瘤(如胶质母细胞瘤)中的应用并非普遍取得显著成功,但新兴的创新策略显示出了希望,人们对其在某些自身免疫性神经疾病中的有效性持乐观态度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验